T-Cell Immunotherapy Market to be Worth USD 30 Billion by 2030, Predicts Roots Analysis

Mohali, Punjab, India, October 13, 2015 --(PR.com)-- After the early success of Immune Checkpoint Inhibitors, T-cell immunotherapy has emerged as another innovative and potent arm of the immuno-oncology market. Characterised by key features such as target specificity, adaptability and memory, T-cells have been effectively used as tools to mediate an immune response.

According to a recent report published by Roots Analysis, there are close to 180 therapies across various phases of development. The study offers a comprehensive analysis of the future outlook of CAR-T, TCR and TIL therapies. Apurva Bhardwaj, the principal analyst, stated, “The likely growth is supported by a robust and opportunistic pipeline targeting various indications. The T-cell therapy market is expected to make a huge leap over the coming decade and be worth USD 30 billion by 2030. Innovative research, lucrative rounds of VC funding, discovery of several novel targets and encouraging clinical trial results have emerged as the key drivers of this market.”

Bhardwaj added, “Academicians across the globe have significantly contributed by convening the initial research; this has served as the framework for several start-ups to drive the research forward. Kite Pharma is the current flag-bearer; Novartis, Juno Therapeutics, CBMG, Celyad, Lion Biotechnologies, Immunocore and Adaptimmune are amongst other well-known players. Several other industry players, which have clinical / preclinical molecules, include
- Altor BioScience
- Applied Immune Technologies
- Autolus
- Bellicum Pharmaceuticals
- BioNtec
- bluebird bio
- CARsgen
- Celdara Medical
- Cell Therapy Catapult
- Cellectis
- Eureka Therapeutics
- Formula Pharmaceuticals
- Molmed
- Mustang Therapeutics
- Oxford Biomedica
- Takara Bio
- Theravectys
- TILT Biotherapeutics
- TNK Therapeutics
- Unum Therapeutics
- ZIOPHARM Oncology"

Funding from VC firms and strategic investors has been a key enabler behind this evolution. The report confirms that, over the last six years, close to USD 3 billion was invested across several start-ups; this trend is unlikely to subside in the near future. In addition, the market is also seeing a growing interest from several technology providers, especially those with capabilities in genome editing and gene transfer, which have developed innovative platforms for engineering of T-cells.

The 419 page report includes detailed profiles and an assessment of the clinical research pipeline of many academic institutes and companies. For additional details, please visit

http://www.rootsanalysis.com/reports/view_document/t-cell-immunotherapy-market-2015-2030/108.html

or email sales@rootsanalysis.com